Eric Mersmann is a litigation associate in the firm’s Chicago office. He focuses his practice on complex commercial litigation with a particular emphasis on patent and trademark matters.
Since joining Winston, Mr. Mersmann has litigated a number of patent matters. Mr. Mersmann was part of a Winston & Strawn team that successfully asserted a patent relating to computer chipset technology against Apple. The jury in OPTi v. Apple rejected Apple’s defenses and awarded Winston & Strawn’s client OPTi 100 percent of the requested damages.
Mr. Mersmann was also on the Winston & Strawn trial team in Aventis Pharma, S.A. and Sanofi-aventis Inc. v. Hospira Inc. successfully representing defendant Hospira against patent infringement claims for a pharmaceutical involving the anti-cancer drug docetaxel.
Recently, Mr. Mersmann represented Monsanto Company in a four-week jury trial against DuPont relating to Monsanto’s Roundup Ready® technology for herbicide tolerance. The jury rejected DuPont’s allegations that Monsanto’s patent was invalid and unenforceable, and found that DuPont infringed Monsanto’s patented technology, awarding a significant amount in damages to Monsanto.
Mr. Mersmann received a B.B.A., with honors, in Marketing from the University of Cincinnati in 2002 and a J.D. in 2005 from the University of Chicago Law School.